The Breath project (Project Number: 2022-1-PL01-KA220-HED-000089283) has been Co-funded by the European Union. Views and opinions expressed are however those of the author or authors only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System. Neither the European Union nor the entity providing the grant can be held responsible for them.

Patient Support Service via SMS

Choose one of the available languages:
Institution
Boehringer Ingelheim
Institution Typology
Rehabilitation Center
Country
Spain
Description
Patient Support Service via SMS. A free service from Boehringer Ingelheim to support patient education in the management of pulmonary fibrosis. PATSU (PATient SUpport service) is a new service from Boehringer Ingelheim to support patient education in the management of pulmonary fibrosis and improve their adherence to treatment by sending free educational content to their cell phone. Patients will receive an SMS with a link to the selected educational content. Patients will be able to consult the content whenever he/she wants, as many times as he/she wants.
Disease
Interstitial lung disease
Activity level
Low
Activity Typology
Home-based activities
Motivation Tools
Available
Innovation
Patient Support Service via SMS
A free service from Boehringer Ingelheim to support patient education in the management of pulmonary fibrosis.
PATSU (PATient SUpport service) is a new service from Boehringer Ingelheim to support patient education in the management of pulmonary fibrosis and improve their adherence to treatment by sending free educational content to their cell phone.
Patients will receive an SMS with a link to the selected educational content.
Patients will be able to consult the content whenever he/she wants, as many times as he/she wants.

Evaluation System
The application offers a contact point for medical professionals to answer questions.

Assessment
Boehringer Ingelheim is committed to providing a website that is accessible to the widest possible audience, regardless of technology or ability. They are actively working to increase the accessibility and usability of our website and in doing so adhere to many of the available standards and guidelines. These guidelines explain how to make web content more accessible for people with disabilities. Conformance with these guidelines will help make the web more user friendly for all people. They are continually seeking out solutions that will bring all areas of the site up to the same level of overall web accessibility.

References
www.avancesenfibrosispulmonar.com/servicio_patsu?tipo=pro
- Flaherty KR, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.
- Patterson KC, et al. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-370.
- Caban JJ, et al. Monitoring pulmonary fibrosis by fusing clinical, physiological, and computed tomography features. Conf Proc IEEE Eng Med Biol Soc. 2011;6216-6219.
- Wells AU, et al. on behalf of the IPF Consensus Working Group. Eur Resp J. 2018;51:1800692.
- Demedts M, et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl. 2001;18(suppl32):2s-16s.
- Cottin V, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076.
Log in to comment >>